BioSpace News Archive

Concord Technologies, a leading provider of cloud-based fax and intelligent document automation software for healthcare providers and enterprises in other regulated industries, announced today the appointment of Christopher Larkin as Chief Technology Officer (CTO)

Chiesi’s CSR program increases contributions to the Triangle community and therapeutic areas

Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that CEO, Brent Vaughan, will participate in a digital therapeutics panel discussion at the Cowen and Company 40th Annual Healthcare Conference with executives from Akili Interactive Labs, Click Therapeutics and Pear Therapeutics

Wave Neuroscience, Inc., a global leader in developing personalized, noninvasive technology aimed at addressing neurological disorders and enhancing cognitive brain function through Transcranial Magnetic Stimulation (TMS), announced today that it has acquired the assets of NeoSync, Inc.

Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President & CEO, will present at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4th, 2020 at 3:00pm ET in Boston.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has elected president and chief executive officer Marc N. Casper, 51, as chairman, effective immediately

The Mollie Biggane Melanoma Foundation and the AIM at Melanoma Foundation have partnered to create and produce “What is Ocular Melanoma?” This free brochure illustrates the locations within the eye where the disease occurs, describes symptoms, and presents risk factors.

CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Cowen & Co. 40 th Annual Health Care Conference on Monday, March 2, 2020 in Boston, Massachusetts and the 30 th Annual Oppenheimer Healthcare Conference on Wednesday, March 18, 2020 in New York. Pre

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced additional interim data from its Phase I pharmacokinetic/pharmacodynamic (PK/PD) studies of Intranasal Racemic Ketamine (SLS-002).

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the year ended December 31, 2019, after the stock market closes on Tuesday, March 10, 2020.